In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
In vitro diagnosis of susceptibility to malignant hyperthermia : evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium. / ØRding, H.; Skovgaard, L. T.
In: Acta Anaesthesiologica Scandinavica Supplementum, Vol. 31, No. 5, 07.1987, p. 462-465.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - In vitro diagnosis of susceptibility to malignant hyperthermia
T2 - evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethonium
AU - ØRding, H.
AU - Skovgaard, L. T.
PY - 1987/7
Y1 - 1987/7
N2 - Susceptibility to MH was determined in 77 patients according to the protocol of the European MH Group. Additional muscle bundles were used for diagnostic in vitro tests with caffeine in the presence of 1 % halothane, potassium chloride, suxamethonium, and caffeine‐suxamethonium. Significant differences between MH‐susceptible (MH) and MH‐negative (MHN) patients were obtained with the halothane‐caffeine test and the potassium chloride test, whereas no differences were found with the suxamethonium test. In the test with caffeine‐suxamethonium, a different response to caffeine but not to suxamethonium was obtained. In all tests there was an overlap in results between MHS and MHN groups, and the predictive values of the tests ranged between 63 and 95%. Prior small doses of caffeine followed by a 4 mmol/l dose of caffeine elicited significantly smaller contractures than 4 mmol/l given as the first dose of caffeine. This underlines the necessity of a common protocol for performance and interpretation of diagnostic tests for MH.
AB - Susceptibility to MH was determined in 77 patients according to the protocol of the European MH Group. Additional muscle bundles were used for diagnostic in vitro tests with caffeine in the presence of 1 % halothane, potassium chloride, suxamethonium, and caffeine‐suxamethonium. Significant differences between MH‐susceptible (MH) and MH‐negative (MHN) patients were obtained with the halothane‐caffeine test and the potassium chloride test, whereas no differences were found with the suxamethonium test. In the test with caffeine‐suxamethonium, a different response to caffeine but not to suxamethonium was obtained. In all tests there was an overlap in results between MHS and MHN groups, and the predictive values of the tests ranged between 63 and 95%. Prior small doses of caffeine followed by a 4 mmol/l dose of caffeine elicited significantly smaller contractures than 4 mmol/l given as the first dose of caffeine. This underlines the necessity of a common protocol for performance and interpretation of diagnostic tests for MH.
KW - Anesthetics
KW - caffeine
KW - halothane
KW - malignant hyperthermia
KW - potassium chloride
KW - suxamethonium
UR - http://www.scopus.com/inward/record.url?scp=0023255505&partnerID=8YFLogxK
U2 - 10.1111/j.1399-6576.1987.tb02604.x
DO - 10.1111/j.1399-6576.1987.tb02604.x
M3 - Journal article
C2 - 3630591
AN - SCOPUS:0023255505
VL - 31
SP - 462
EP - 465
JO - Acta Anaesthesiologica Scandinavica
JF - Acta Anaesthesiologica Scandinavica
SN - 0001-5172
IS - 5
ER -
ID: 259166678